Full-year results to 31 March were in line with the trading update in February, which indicated an adjusted EBITDA loss of between £2.1m and £2.3m although revenues were c.£0.6m lower than indicated at the time. Cash at 31 March was £5.8m, which should be sufficient for the company to exploit its core activities in food intolerance testing and its Global Health business (point of care lateral flow COVID-19 and CD4 tests). Despite the COVID-19 disruption to its Health & Nutrition business, there ....
13 Jul 2021
Omega Diagnostics - FY 2021 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Omega Diagnostics - FY 2021 results
Cambridge Nutritional Sciences PLC (CNSL:LON) | 3.4 0 0.0% | Mkt Cap: 8.21m
- Published:
13 Jul 2021 -
Author:
Mark Brewer | Cavendish Research -
Pages:
14
Full-year results to 31 March were in line with the trading update in February, which indicated an adjusted EBITDA loss of between £2.1m and £2.3m although revenues were c.£0.6m lower than indicated at the time. Cash at 31 March was £5.8m, which should be sufficient for the company to exploit its core activities in food intolerance testing and its Global Health business (point of care lateral flow COVID-19 and CD4 tests). Despite the COVID-19 disruption to its Health & Nutrition business, there ....